Skip to main content

Clearside Biomedical, Inc.

CLSDDelisted Dec 8, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001539029

Clearside Biomedical, Inc. was delisted on Dec 8, 2025; its insiders filed their last Form 4 on Feb 24, 2025; 26 institutions reported holding it in 13F filings for Q3 2025, worth $2.18M in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
26
Q3 2025, −18 vs. previous quarter
13F value
$2.18M
Reported value at the end of Q3 2025
Superinvestors holding
0
At the end of Q3 2025

Superinvestors holding CLSD, Q3 2025

Go to the superinvestors tab

No superinvestor reported holding CLSD at the end of Q3 2025.

Latest insider trades

Open-market purchases and sales by Clearside Biomedical, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 24, 2025 (view filing)Feb 24Same dayThorp ClayDirectorPPurchase+15.0K$0.92+$13.8K+9.3%176.1K after
Nov 4, 2024 (view filing)Nov 13 daysChong Ngai Hang VictorChief Medical OfficerPPurchase+36.5K$1.00+$36.5K+57.5%100.0K after
Jun 24, 2024 (view filing)Jun 24Same dayChong Ngai Hang VictorChief Medical OfficerPPurchase+23.5K$1.06+$24.9K+58.8%63.5K after
May 15, 2024 (view filing)May 15Same dayYerxa Benjamin RDirectorPPurchase+7.81K$1.31+$10.2K+77.0%18.0K after
Apr 19, 2024 (view filing)Apr 17-182 daysGibney Anthony SDirectorPPurchase+100.0K$1.30+$129.7KNew position100.0K after2 lots
Mar 20, 2024 (view filing)Mar 20Same dayChong Ngai Hang VictorCHIEF MEDICAL OFFICERPPurchase+30.0K$1.60+$48.0KNew position30.0K after
Feb 9, 2024 (view filing)Feb 72 daysWhitmore Bradford T10% OwnerPPurchase+444.4K$1.35+$600.0K+11.0%4.50M after
Feb 9, 2024 (view filing)Feb 72 daysWhitmore Bradford T10% OwnerPPurchase+444.4K$0.00$0–444.4K afterDerivative
Jan 19, 2024 (view filing)Jan 19Same dayLasezkay George MCEOSSale−18.0K$1.27−$22.9K−3.7%466.6K after
Jan 19, 2024 (view filing)Jan 19Same dayDeignan Charles A.Chief Financial OfficerSSale−12.9K$1.28−$16.5K−3.2%384.7K after

Top 10 13F holders, Q3 2025

The largest institutional positions in Clearside Biomedical, Inc. at the end of Q3 2025; share changes are against Q2 2025.

See all 26 holders
Institutions holding CLSD in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc221,968$881.2K0.00%−2,236−1.0%ReducedConverted for a 1-for-15 split
Carmignac Gestion100,556$399.2K0.01%00.0%UnchangedConverted for a 1-for-15 split
Geode Capital Management, LLC52,741$209.4K0.00%00.0%UnchangedConverted for a 1-for-15 split
BlackRock, Inc.41,677$165.5K0.00%00.0%UnchangedConverted for a 1-for-15 split
Renaissance Technologies LLC25,247$100.2K0.00%−7,859−23.7%ReducedConverted for a 1-for-15 split
Apollon Wealth Management, LLC23,586$93.6K0.00%+23,586New
First Manhattan Co22,846$90.7K0.00%00.0%UnchangedConverted for a 1-for-15 split
State Street Corp16,387$65.1K0.00%−1,297−7.3%ReducedConverted for a 1-for-15 split
Gsa Capital Partners LLP12,885$51.0K0.00%−22,683−63.8%ReducedConverted for a 1-for-15 split
Northern Trust Corp11,032$43.8K0.00%00.0%UnchangedConverted for a 1-for-15 split

Holders of 5% or more of CLSD

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Clearside Biomedical, Inc..

See all 2 holders and filings
Largest holders of CLSD from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Whitmore Bradford T13G/A8.60%6.52M shares–Mar 4, 20251 filingMar 4, 2025SEC
Wiles Stephen Boyd13G5.20%4.00M sharesNewApr 1, 20251 filingApr 1, 2025SEC